cis-3-Phenylcyclopentylacetic acid | 3974-41-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cis-3-Phenylcyclopentylacetic acid
• 英文别名: (+/-)-(cis-3-phenyl-cyclopentyl)-acetic acid；(+/-)-(cis-3-Phenyl-cyclopentyl)-essigsaeure；2-[(1S,3R)-3-phenylcyclopentyl]acetic acid
• CAS: 3974-41-2；35444-83-8
• 化学式: C₁₃H₁₆O₂
• 分子量: 204.269
• InChiKey: JYWGHXMCVRPOJH-CMPLNLGQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.05
• 重原子数：
  15.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  37.3
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为产物：
  描述：

  2-环戊烯基-1-乙酸 在 三氯化铝 、 硝基甲烷 作用下， 反应 1.13h， 生成 cis-3-Phenylcyclopentylacetic acid
  参考文献：
  名称：

  Razus, Alexandru C.; Arvay, Zsolt; Birzan, Liviu, Revue Roumaine de Chimie, 1992, vol. 37, # 11-12, p. 1259 - 1266

  摘要：

  DOI：

文献信息

• Winternitz; Mousseron, Bulletin de la Societe Chimique de France, 1949, p. 713,717
  作者：Winternitz、Mousseron

  DOI：——

  日期：——
• Drug interaction studies between paclitaxel (Taxol) and OC144-093 — A new modulator of MDR in cancer chemotherapy
  作者：Emma S. Guns、Tetyana Denyssevych、Ross Dixon、Marcel B. Bally、Lawrence Mayer

  DOI：10.1007/bf03190426

  日期：2002.6

  The MDR modulator, OC144-093, is a potential candidate for use in cancer therapy and exhibits potent biological activity in vitro and in vivo when combined with anticancer agents such as paclitaxel [1]. Its inhibitory interaction with P-glycoprotein (Pgp), the mdr1 gene product and a mechanistic participant in multidrug resistance[2], underlies its activity as a modulator of MDR. Having previously shown that OC144-093 is not a substrate for CYP3A [4] we first examined the effects of OC144-093 on paclitaxel metabolism in vitro. Using human liver microsomes, we have demonstrated that OC144-093 inhibited the CYP3A mediated metabolism of paclitaxel at high concentrations only (Ki = 39.8+/-5.1 muM, n=3). Pharmacokinetic results also show that an oral dose of OC144-093, co-administered with paclitaxel caused negligible disturbance of the pharmacokinetic profile for paclitaxel when injected intravenously. In contrast, AUC values were elevated approximately 1.5-fold in all groups treated orally with paclitaxel and OC144-093. Cmax was enhanced approximately 2-fold in the co-dosed group. These characteristics are consistent with Pgp blockade in the gut enhancing oral bioavailability. Elimination proper-ties of paclitaxel were affected only upon multiple dosing of OC144-093. These results warrant the further clinical assessment of OC144-093 as an MDR reversing agent.